Bausch Health Companies Inc. (BHC) Current Ratio
- Current ratio · latest quarter: Value 1.44×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.44× | Current assets / current liabilities. $6.52B ÷ $4.54B ≈ 1.44× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 6.52B USD | Assets, Current |
| Current obligations | 4.54B USD | Liabilities, Current |
| Cash and equivalents | 1.82B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 1.60B USD | Inventory, Net |
| Payables | 593.00M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 866.00M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.52B | $4.54B | $1.82B | (m) | (m) | $1.60B | $593.00M | $866.00M | 1.44× |
| 2026-03-31 | $5.98B | $4.53B | $1.30B | (m) | (m) | $1.60B | $593.00M | $889.00M | 1.32× |
| 2025-12-31 | $6.16B | $4.18B | $1.31B | (m) | (m) | $1.63B | $600.00M | $225.00M | 1.47× |
| 2025-09-30 | $6.25B | $4.79B | $1.31B | (m) | (m) | $1.60B | $616.00M | $579.00M | 1.30× |
| 2025-06-30 | $6.51B | $4.97B | $1.73B | (m) | (m) | $1.66B | $627.00M | $879.00M | 1.31× |
| 2025-03-31 | $5.73B | $4.26B | $1.13B | (m) | (m) | $1.61B | $620.00M | $282.00M | 1.35× |
| 2024-12-31 | $5.77B | $6.75B | $1.18B | (m) | (m) | $1.59B | $589.00M | $2.67B | 0.86× |
| 2024-09-30 | $5.35B | $4.51B | $719.00M | (m) | (m) | $1.66B | $667.00M | $453.00M | 1.19× |
| 2024-06-30 | $5.21B | $4.37B | $595.00M | (m) | (m) | $1.61B | $579.00M | $452.00M | 1.19× |
| 2024-03-31 | $5.40B | $4.41B | $733.00M | (m) | (m) | $1.64B | $642.00M | $538.00M | 1.22× |
| 2023-12-31 | $5.60B | $4.30B | $947.00M | (m) | (m) | $1.54B | $719.00M | $450.00M | 1.30× |
| 2023-09-30 | $5.05B | $4.22B | $760.00M | (m) | (m) | $1.27B | $569.00M | $536.00M | 1.20× |
| 2023-06-30 | $4.46B | $3.97B | $579.00M | (m) | (m) | $1.24B | $515.00M | $444.00M | 1.12× |
| 2023-03-31 | $4.24B | $3.92B | $518.00M | (m) | (m) | $1.22B | $561.00M | $446.00M | 1.08× |
| 2022-12-31 | $4.25B | $3.94B | $564.00M | (m) | (m) | $1.09B | $521.00M | $432.00M | 1.08× |
| 2022-09-30 | $4.01B | $3.83B | $486.00M | (m) | (m) | $1.06B | $486.00M | $411.00M | 1.05× |
| 2022-06-30 | $5.42B | $5.00B | $659.00M | (m) | (m) | $1.07B | $536.00M | $150.00M | 1.08× |
| 2022-03-31 | $5.84B | $4.77B | $1.25B | (m) | (m) | $1.04B | $471.00M | $0.00 | 1.22× |
| 2021-12-31 | $5.61B | $5.20B | $582.00M | (m) | (m) | $993.00M | $407.00M | $0.00 | 1.08× |
| 2021-09-30 | $5.32B | $5.44B | $690.00M | (m) | (m) | $1.06B | $455.00M | $0.00 | 0.98× |
| 2021-06-30 | $5.45B | $5.52B | $642.00M | (m) | (m) | $1.09B | $442.00M | $0.00 | 0.99× |
| 2021-03-31 | $5.39B | $4.90B | $679.00M | (m) | (m) | $1.08B | $342.00M | $0.00 | 1.10× |
| 2020-12-31 | $5.34B | $4.91B | $605.00M | (m) | (m) | $1.09B | $337.00M | $0.00 | 1.09× |
| 2020-09-30 | $5.67B | $4.73B | $977.00M | (m) | (m) | $1.22B | $379.00M | $0.00 | 1.20× |
| 2020-06-30 | $5.28B | $4.72B | $896.00M | (m) | (m) | $1.23B | $447.00M | $1.00M | 1.12× |
| 2020-03-31 | $5.50B | $4.89B | $912.00M | (m) | (m) | $1.12B | $444.00M | $4.00M | 1.13× |
| 2019-12-31 | $6.97B | $6.25B | $3.24B | (m) | (m) | $1.11B | $503.00M | $1.23B | 1.12× |
| 2019-09-30 | $4.30B | $3.73B | $825.00M | (m) | (m) | $1.10B | $437.00M | $100.00M | 1.15× |
| 2019-06-30 | $4.47B | $3.71B | $878.00M | (m) | (m) | $1.06B | $527.00M | $56.00M | 1.21× |
| 2019-03-31 | $4.28B | $3.94B | $782.00M | (m) | (m) | $1.01B | $429.00M | $257.00M | 1.08× |
| 2018-12-31 | $4.21B | $3.84B | $721.00M | (m) | (m) | $934.00M | $411.00M | $228.00M | 1.10× |
| 2018-09-30 | $4.74B | $4.16B | $973.00M | (m) | (m) | $971.00M | $440.00M | $298.00M | 1.14× |
| 2018-06-30 | $4.64B | $4.07B | $838.00M | (m) | (m) | $993.00M | $417.00M | $230.00M | 1.14× |
| 2018-03-31 | $4.72B | $3.99B | $909.00M | (m) | (m) | $1.04B | $428.00M | $2.00M | 1.18× |
| 2017-12-31 | $4.75B | $4.27B | $720.00M | (m) | (m) | $1.05B | $365.00M | $209.00M | 1.11× |
| 2017-09-30 | $5.94B | $4.73B | $964.00M | (m) | (m) | $1.07B | $407.00M | $925.00M | 1.26× |
| 2017-06-30 | $5.99B | $4.46B | $1.21B | (m) | (m) | $1.08B | $371.00M | $813.00M | 1.34× |
| 2017-03-31 | $5.33B | $4.25B | $1.21B | (m) | (m) | $1.11B | $368.00M | $346.00M | 1.26× |
| 2016-12-31 | $5.08B | $3.61B | $542.00M | (m) | (m) | $1.06B | $324.00M | $1.00M | 1.41× |
| 2016-09-30 | $5.67B | $3.90B | $658.50M | (m) | (m) | $1.30B | $358.70M | $59.00M | 1.46× |
| 2016-06-30 | $5.82B | $4.23B | $852.40M | (m) | (m) | $1.34B | $425.90M | $294.10M | 1.38× |
| 2016-03-31 | $6.23B | $4.60B | $1.31B | (m) | (m) | $1.32B | $438.10M | $675.10M | 1.36× |
| 2015-12-31 | $5.51B | $5.31B | $597.00M | (m) | (m) | $1.26B | $434.00M | $823.00M | 1.04× |
| 2015-09-30 | $7.00B | $4.65B | $1.42B | (m) | (m) | $1.20B | $476.80M | $707.00M | 1.50× |
| 2015-06-30 | $6.35B | $4.29B | $958.00M | (m) | (m) | $1.23B | $415.80M | $590.90M | 1.48× |
| 2015-03-31 | $16.19B | $3.10B | $1.86B | (m) | (m) | $998.90M | $352.50M | $122.80M | 5.23× |
| 2014-12-31 | $4.13B | $2.71B | $322.60M | (m) | $2.08B | $889.20M | $398.00M | $900.00K | 1.53× |
| 2014-09-30 | $4.41B | $3.14B | $808.80M | (m) | (m) | $932.70M | $323.30M | $690.60M | 1.40× |
| 2014-06-30 | $5.16B | $2.50B | $531.20M | (m) | (m) | $942.50M | $327.70M | $266.70M | 2.07× |
| 2014-03-31 | $3.95B | $2.56B | $576.30M | (m) | (m) | $953.40M | $392.30M | $238.90M | 1.54× |
| 2013-12-31 | $3.89B | $2.51B | $600.30M | (m) | $1.68B | $883.00M | $327.00M | $204.80M | 1.55× |
| 2013-09-30 | $3.85B | $2.85B | $596.35M | (m) | (m) | $1.08B | $412.94M | $360.96M | 1.35× |
| 2013-06-30 | $4.53B | $1.76B | $2.54B | (m) | (m) | $497.06M | $284.54M | $346.88M | 2.57× |
| 2013-03-31 | $2.37B | $1.65B | $413.74M | (m) | (m) | $509.68M | $183.02M | $289.68M | 1.44× |
| 2012-12-31 | $2.78B | $1.82B | $916.09M | (m) | $769.47M | $531.26M | $227.38M | $480.18M | 1.52× |
| 2012-09-30 | $1.71B | $1.16B | $257.73M | (m) | (m) | $418.25M | $166.69M | $207.69M | 1.48× |
| 2012-06-30 | $1.63B | $1.05B | $395.27M | (m) | (m) | $388.73M | $156.18M | $195.15M | 1.55× |
| 2012-03-31 | $1.53B | $957.93M | $330.48M | $1.05M | (m) | $373.53M | $156.28M | $145.06M | 1.60× |
| 2011-12-31 | $1.36B | $924.27M | $164.11M | $6.34M | $468.54M | $355.21M | $157.62M | $111.25M | 1.47× |
| 2011-09-30 | $1.10B | $862.67M | $254.56M | $2.97M | (m) | $259.65M | $148.78M | $38.94M | 1.27× |
| 2011-06-30 | $1.05B | $761.89M | $238.94M | $2.95M | (m) | $259.78M | $126.71M | $17.50M | 1.37× |
| 2011-03-31 | $1.27B | $661.47M | $401.75M | $4.30M | (m) | $266.13M | $116.12M | $17.22M | 1.93× |
| 2010-12-31 | $1.02B | $692.46M | $394.27M | $6.08M | $234.02M | $229.58M | $101.32M | $116.90M | 1.47× |
| 2010-09-30 | $1.30B | $845.92M | $592.65M | $5.59M | (m) | $295.28M | $175.99M | $121.59M | 1.54× |
| 2010-06-30 | $414.44M | $234.24M | $176.57M | $6.24M | (m) | $88.13M | $41.88M | $16.28M | 1.77× |
| 2009-12-31 | $342.89M | $249.15M | $114.46M | $9.57M | (m) | $82.77M | $72.02M | $12.11M | 1.38× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |